Loading…
Treatment of Post Transfusion Graft‐Versus‐Host Disease
Background and Objectives: In Japan, so many cases of post‐transfusion graft‐versus‐host disease (PT‐GVHD) have been reported, and no effective treatment has been reported. Materials and Methods: Results: Totally 61 cases of PT‐GVHD have been collected, and their background were analyzed. A serine p...
Saved in:
| Published in: | Vox sanguinis 2000-01, Vol.78 (S2), p.277-279 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3739-c0ea6e94d6ff043824cf930b0f8e09a591fc8246872013a4be4b422e4fda8ee03 |
| container_end_page | 279 |
| container_issue | S2 |
| container_start_page | 277 |
| container_title | Vox sanguinis |
| container_volume | 78 |
| creator | Juji, Takeo Nishimura, Motoko Tadokoro, Kenji |
| description | Background and Objectives:
In Japan, so many cases of post‐transfusion graft‐versus‐host disease (PT‐GVHD) have been reported, and no effective treatment has been reported.
Materials and Methods: Results:
Totally 61 cases of PT‐GVHD have been collected, and their background were analyzed. A serine protease inhibitor, nafamostat mesilate(N.M.) was examined as a drug for treatment of PT‐GVHD using 4 patients.
Results:
N.M. was confirmed to inhibit cytotoxic activities of established cytotoxic T cell (CTL) clones in vitro. Simultaneously it was confirmed that fever and skin rash disappeared and liver function tests were normalized soon after the administration of N.M. in all four cases. Leukopenia and thrombocytopenia simultaneously improved.
Conclusion:
The effects of N.M. seem to be limited to inhibit cytotoxic activity of CTL. In addition to this drug, how to remove the CTL from the patients will be the essentially important theme for the future. |
| doi_str_mv | 10.1111/j.1423-0410.2000.tb00079.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223488233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57454498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3739-c0ea6e94d6ff043824cf930b0f8e09a591fc8246872013a4be4b422e4fda8ee03</originalsourceid><addsrcrecordid>eNqVkN1OwjAUgBujEURfwSzE282uLaPVK0EBExK8QOJd043TZAts2G4R7nwEn9EnsXOLemsv-nPOd3pOPoT6IQ5Ct66zIGSE-pi5AMEYB2Xs9qEI9keo-5M6Rl2MGfGFS3XQmbWZgzjhg1PUCbGgXESii26XBlS5hbz0Cu09Fbb0lkblVlc2LXJvapQuP98_VmBsZd1lVhP3qQVl4RydaLWxcNGePfQ8eViOZ_58MX0c3839hA6p8BMMKgLB1pHWmFFOWKIFxTHWHLBQAxHqxAUjPiQ4pIrFwGJGCDC9VhwA0x7qN__uTPFagS1lVlQmdy0lIZRxTih10E0DJaaw1oCWO5NulTnIEMtam8xk7UbWbmStTbba5N4VX7YdqngL6z-ljScHXLWAsonaaKcoSe0vx7gQvB5i1GBv6QYO_5hArhYvo8n3g34BVzWLUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223488233</pqid></control><display><type>article</type><title>Treatment of Post Transfusion Graft‐Versus‐Host Disease</title><source>Wiley</source><creator>Juji, Takeo ; Nishimura, Motoko ; Tadokoro, Kenji</creator><creatorcontrib>Juji, Takeo ; Nishimura, Motoko ; Tadokoro, Kenji</creatorcontrib><description>Background and Objectives:
In Japan, so many cases of post‐transfusion graft‐versus‐host disease (PT‐GVHD) have been reported, and no effective treatment has been reported.
Materials and Methods: Results:
Totally 61 cases of PT‐GVHD have been collected, and their background were analyzed. A serine protease inhibitor, nafamostat mesilate(N.M.) was examined as a drug for treatment of PT‐GVHD using 4 patients.
Results:
N.M. was confirmed to inhibit cytotoxic activities of established cytotoxic T cell (CTL) clones in vitro. Simultaneously it was confirmed that fever and skin rash disappeared and liver function tests were normalized soon after the administration of N.M. in all four cases. Leukopenia and thrombocytopenia simultaneously improved.
Conclusion:
The effects of N.M. seem to be limited to inhibit cytotoxic activity of CTL. In addition to this drug, how to remove the CTL from the patients will be the essentially important theme for the future.</description><identifier>ISSN: 0042-9007</identifier><identifier>EISSN: 1423-0410</identifier><identifier>DOI: 10.1111/j.1423-0410.2000.tb00079.x</identifier><identifier>PMID: 10938969</identifier><identifier>CODEN: VOSAAD</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - standards ; Biological and medical sciences ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Drug Evaluation ; Female ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - epidemiology ; Graft vs Host Disease - etiology ; Guanidines - administration & dosage ; Guanidines - adverse effects ; Guanidines - standards ; Humans ; Male ; Medical sciences ; Middle Aged ; Serine Proteinase Inhibitors - adverse effects ; Serine Proteinase Inhibitors - standards ; Serine Proteinase Inhibitors - therapeutic use ; Transfusion Reaction ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Treatment Outcome</subject><ispartof>Vox sanguinis, 2000-01, Vol.78 (S2), p.277-279</ispartof><rights>2000 S. Karger AG, Basel</rights><rights>2000 INIST-CNRS</rights><rights>Copyright S. Karger AG Jul 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3739-c0ea6e94d6ff043824cf930b0f8e09a591fc8246872013a4be4b422e4fda8ee03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1489983$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10938969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Juji, Takeo</creatorcontrib><creatorcontrib>Nishimura, Motoko</creatorcontrib><creatorcontrib>Tadokoro, Kenji</creatorcontrib><title>Treatment of Post Transfusion Graft‐Versus‐Host Disease</title><title>Vox sanguinis</title><addtitle>Vox Sang</addtitle><description>Background and Objectives:
In Japan, so many cases of post‐transfusion graft‐versus‐host disease (PT‐GVHD) have been reported, and no effective treatment has been reported.
Materials and Methods: Results:
Totally 61 cases of PT‐GVHD have been collected, and their background were analyzed. A serine protease inhibitor, nafamostat mesilate(N.M.) was examined as a drug for treatment of PT‐GVHD using 4 patients.
Results:
N.M. was confirmed to inhibit cytotoxic activities of established cytotoxic T cell (CTL) clones in vitro. Simultaneously it was confirmed that fever and skin rash disappeared and liver function tests were normalized soon after the administration of N.M. in all four cases. Leukopenia and thrombocytopenia simultaneously improved.
Conclusion:
The effects of N.M. seem to be limited to inhibit cytotoxic activity of CTL. In addition to this drug, how to remove the CTL from the patients will be the essentially important theme for the future.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - standards</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - epidemiology</subject><subject>Graft vs Host Disease - etiology</subject><subject>Guanidines - administration & dosage</subject><subject>Guanidines - adverse effects</subject><subject>Guanidines - standards</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Serine Proteinase Inhibitors - adverse effects</subject><subject>Serine Proteinase Inhibitors - standards</subject><subject>Serine Proteinase Inhibitors - therapeutic use</subject><subject>Transfusion Reaction</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Treatment Outcome</subject><issn>0042-9007</issn><issn>1423-0410</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqVkN1OwjAUgBujEURfwSzE282uLaPVK0EBExK8QOJd043TZAts2G4R7nwEn9EnsXOLemsv-nPOd3pOPoT6IQ5Ct66zIGSE-pi5AMEYB2Xs9qEI9keo-5M6Rl2MGfGFS3XQmbWZgzjhg1PUCbGgXESii26XBlS5hbz0Cu09Fbb0lkblVlc2LXJvapQuP98_VmBsZd1lVhP3qQVl4RydaLWxcNGePfQ8eViOZ_58MX0c3839hA6p8BMMKgLB1pHWmFFOWKIFxTHWHLBQAxHqxAUjPiQ4pIrFwGJGCDC9VhwA0x7qN__uTPFagS1lVlQmdy0lIZRxTih10E0DJaaw1oCWO5NulTnIEMtam8xk7UbWbmStTbba5N4VX7YdqngL6z-ljScHXLWAsonaaKcoSe0vx7gQvB5i1GBv6QYO_5hArhYvo8n3g34BVzWLUA</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>Juji, Takeo</creator><creator>Nishimura, Motoko</creator><creator>Tadokoro, Kenji</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope></search><sort><creationdate>20000101</creationdate><title>Treatment of Post Transfusion Graft‐Versus‐Host Disease</title><author>Juji, Takeo ; Nishimura, Motoko ; Tadokoro, Kenji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3739-c0ea6e94d6ff043824cf930b0f8e09a591fc8246872013a4be4b422e4fda8ee03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - standards</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - epidemiology</topic><topic>Graft vs Host Disease - etiology</topic><topic>Guanidines - administration & dosage</topic><topic>Guanidines - adverse effects</topic><topic>Guanidines - standards</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Serine Proteinase Inhibitors - adverse effects</topic><topic>Serine Proteinase Inhibitors - standards</topic><topic>Serine Proteinase Inhibitors - therapeutic use</topic><topic>Transfusion Reaction</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Juji, Takeo</creatorcontrib><creatorcontrib>Nishimura, Motoko</creatorcontrib><creatorcontrib>Tadokoro, Kenji</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Vox sanguinis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juji, Takeo</au><au>Nishimura, Motoko</au><au>Tadokoro, Kenji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Post Transfusion Graft‐Versus‐Host Disease</atitle><jtitle>Vox sanguinis</jtitle><addtitle>Vox Sang</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>78</volume><issue>S2</issue><spage>277</spage><epage>279</epage><pages>277-279</pages><issn>0042-9007</issn><eissn>1423-0410</eissn><coden>VOSAAD</coden><abstract>Background and Objectives:
In Japan, so many cases of post‐transfusion graft‐versus‐host disease (PT‐GVHD) have been reported, and no effective treatment has been reported.
Materials and Methods: Results:
Totally 61 cases of PT‐GVHD have been collected, and their background were analyzed. A serine protease inhibitor, nafamostat mesilate(N.M.) was examined as a drug for treatment of PT‐GVHD using 4 patients.
Results:
N.M. was confirmed to inhibit cytotoxic activities of established cytotoxic T cell (CTL) clones in vitro. Simultaneously it was confirmed that fever and skin rash disappeared and liver function tests were normalized soon after the administration of N.M. in all four cases. Leukopenia and thrombocytopenia simultaneously improved.
Conclusion:
The effects of N.M. seem to be limited to inhibit cytotoxic activity of CTL. In addition to this drug, how to remove the CTL from the patients will be the essentially important theme for the future.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>10938969</pmid><doi>10.1111/j.1423-0410.2000.tb00079.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9007 |
| ispartof | Vox sanguinis, 2000-01, Vol.78 (S2), p.277-279 |
| issn | 0042-9007 1423-0410 |
| language | eng |
| recordid | cdi_proquest_journals_223488233 |
| source | Wiley |
| subjects | Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - standards Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Drug Evaluation Female Graft vs Host Disease - drug therapy Graft vs Host Disease - epidemiology Graft vs Host Disease - etiology Guanidines - administration & dosage Guanidines - adverse effects Guanidines - standards Humans Male Medical sciences Middle Aged Serine Proteinase Inhibitors - adverse effects Serine Proteinase Inhibitors - standards Serine Proteinase Inhibitors - therapeutic use Transfusion Reaction Transfusions. Complications. Transfusion reactions. Cell and gene therapy Treatment Outcome |
| title | Treatment of Post Transfusion Graft‐Versus‐Host Disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A02%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Post%20Transfusion%20Graft%E2%80%90Versus%E2%80%90Host%20Disease&rft.jtitle=Vox%20sanguinis&rft.au=Juji,%20Takeo&rft.date=2000-01-01&rft.volume=78&rft.issue=S2&rft.spage=277&rft.epage=279&rft.pages=277-279&rft.issn=0042-9007&rft.eissn=1423-0410&rft.coden=VOSAAD&rft_id=info:doi/10.1111/j.1423-0410.2000.tb00079.x&rft_dat=%3Cproquest_cross%3E57454498%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3739-c0ea6e94d6ff043824cf930b0f8e09a591fc8246872013a4be4b422e4fda8ee03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=223488233&rft_id=info:pmid/10938969&rfr_iscdi=true |